OBJECTIVE: To investigate the relationship between brain microbleeds (MBs) and the rate of cognitive decline in Alzheimer disease (AD). METHODS: In this cohort study, we studied 221 patients with AD with available baseline MRI scans (1.0 or 1.5 T) and at least 2 Mini-Mental State Examinations (MMSE) scores obtained more than 1 year apart from our memory clinic. Mean ± SD follow-up time was 3 ± 1 years, and patients had a median of 4 MMSE scores (range 2-17). We used linear mixed models with sex and age as covariates to investigate whether MBs influenced the rate of cognitive decline. RESULTS: Mean age was 68 ± 9 years, 109 (49%) patients were female, and the baseline MMSE score was 22 ± 4. There were 39 patients (18%) with MBs (median 2, range 1-27) and 182 without. Linear mixed models showed that overall patients declined 2 MMSE points per year. We found no association of the presence of MBs with baseline MMSE or change in MMSE. Adjustment for atrophy, white matter hyperintensities, lacunes, and vascular risk factors did not change the results nor did stratification for MB location, APOE ε4 carriership, or age at onset (≤65 years vs >65 years). Repeating the analyses with number of MBs as predictor rendered similar results. CONCLUSION: MBs did not influence the rate of cognitive decline in patients with AD. The formerly reported increased risk of mortality in patients with MBs seems not to be attributable to a steeper rate of decline per se but might be due to vascular events, including (hemorrhagic) stroke.
OBJECTIVE: To investigate the relationship between brain microbleeds (MBs) and the rate of cognitive decline in Alzheimer disease (AD). METHODS: In this cohort study, we studied 221 patients with AD with available baseline MRI scans (1.0 or 1.5 T) and at least 2 Mini-Mental State Examinations (MMSE) scores obtained more than 1 year apart from our memory clinic. Mean ± SD follow-up time was 3 ± 1 years, and patients had a median of 4 MMSE scores (range 2-17). We used linear mixed models with sex and age as covariates to investigate whether MBs influenced the rate of cognitive decline. RESULTS: Mean age was 68 ± 9 years, 109 (49%) patients were female, and the baseline MMSE score was 22 ± 4. There were 39 patients (18%) with MBs (median 2, range 1-27) and 182 without. Linear mixed models showed that overall patients declined 2 MMSE points per year. We found no association of the presence of MBs with baseline MMSE or change in MMSE. Adjustment for atrophy, white matter hyperintensities, lacunes, and vascular risk factors did not change the results nor did stratification for MB location, APOE ε4 carriership, or age at onset (≤65 years vs >65 years). Repeating the analyses with number of MBs as predictor rendered similar results. CONCLUSION: MBs did not influence the rate of cognitive decline in patients with AD. The formerly reported increased risk of mortality in patients with MBs seems not to be attributable to a steeper rate of decline per se but might be due to vascular events, including (hemorrhagic) stroke.
Authors: Yael D Reijmer; Panagiotis Fotiadis; Sergi Martinez-Ramirez; David H Salat; Aaron Schultz; Ashkan Shoamanesh; Alison M Ayres; Anastasia Vashkevich; Diana Rosas; Kristin Schwab; Alexander Leemans; Geert-Jan Biessels; Jonathan Rosand; Keith A Johnson; Anand Viswanathan; M Edip Gurol; Steven M Greenberg Journal: Brain Date: 2014-11-02 Impact factor: 13.501
Authors: Georgette L Suidan; Pradeep K Singh; Sunita Patel-Hett; Zu-Lin Chen; Dmitri Volfson; Hitomi Yamamoto-Imoto; Erin H Norris; Robert D Bell; Sidney Strickland Journal: Blood Adv Date: 2018-05-08
Authors: Costantino Iadecola; Kristine Yaffe; José Biller; Lisa C Bratzke; Frank M Faraci; Philip B Gorelick; Martha Gulati; Hooman Kamel; David S Knopman; Lenore J Launer; Jane S Saczynski; Sudha Seshadri; Adina Zeki Al Hazzouri Journal: Hypertension Date: 2016-10-10 Impact factor: 10.190
Authors: Saloua Akoudad; Frank J Wolters; Anand Viswanathan; Renée F de Bruijn; Aad van der Lugt; Albert Hofman; Peter J Koudstaal; M Arfan Ikram; Meike W Vernooij Journal: JAMA Neurol Date: 2016-08-01 Impact factor: 18.302
Authors: Sara Shams; Tobias Granberg; Juha Martola; Andreas Charidimou; Xiaozhen Li; Mana Shams; Seyed-Mohammad Fereshtehnejad; Lena Cavallin; Peter Aspelin; Maria Wiberg-Kristoffersen; Lars-Olof Wahlund Journal: J Cereb Blood Flow Metab Date: 2016-07-21 Impact factor: 6.200
Authors: M Buciuc; J R Duffy; M M Machulda; A J Spychalla; J L Gunter; C R Jack; C Giannini; A Raghunathan; D W Dickson; K A Josephs; J L Whitwell Journal: Eur J Neurol Date: 2020-11-12 Impact factor: 6.089
Authors: Jennifer L Whitwell; Kejal Kantarci; Stephen D Weigand; Emily S Lundt; Jeffrey L Gunter; Joseph R Duffy; Edythe A Strand; Mary M Machulda; Anthony J Spychalla; Daniel A Drubach; Ronald C Petersen; Val J Lowe; Clifford R Jack; Keith A Josephs Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472
Authors: Richard Dodel; Axel Rominger; Peter Bartenstein; Frederik Barkhof; Kaj Blennow; Stefan Förster; Yaroslav Winter; Jan-Philipp Bach; Julius Popp; Judith Alferink; Jens Wiltfang; Katharina Buerger; Markus Otto; Piero Antuono; Michael Jacoby; Ralph Richter; James Stevens; Isaac Melamed; Jerome Goldstein; Stefan Haag; Stefan Wietek; Martin Farlow; Frank Jessen Journal: Lancet Neurol Date: 2013-01-31 Impact factor: 44.182